Nycomed Amersham
Issues With Radioactivity
Previous Contents Next
A number of Nycomed Amersham's diagnostic and therapeutic products owe their effectiveness to the use of small amounts of radioactivity, as do some of Amersham Pharmacia Biotech's life science technologies. A wide range of isotopes is used in various products in quantities dependent upon the application. Some of the commonly used isotopes for diagnosis include those of iodine, technetium and thallium; therapeutic isotopes include those of iodine and strontium; life science uses include tritium, carbon 14 and phosphorous 32.

All sites using radionuclides in research or manufacture are strictly regulated by external authorities. These controls embrace the transport, packaging, handling, storage and use of radioisotopes and the management of residues from the production process. All the company's nuclear licensed sites comply fully with the strictly set legal limits for safe discharges and waste storage.

The company has also been investing in new technologies and techniques to improve its radioactive waste management procedures. These include reducing wherever possible the amount generated and storing or disposing of residues to the highest standards. In the UK, this led the company to invest in its own state-of-the-art facility for storage of intermediate level waste until a Government approved facility is constructed.

Home | Foreword | Introduction | Principal Businesses & Products | HS&E Management | HS&E Policy |
HS&E Standards | Implementing the Policy | Issues with Radioactivity | Management of Radioactive Waste | Discharges of Radioactivity | Social & Community Responsibilities | Achievements to Date |
The Way Forward | Further Information | Appendices
Return To Main Site
Previous Next